Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-07-19
2011-07-19
Aeder, Sean E (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
Reexamination Certificate
active
07981621
ABSTRACT:
The present invention relates to the use of matrix metalloproteinase 7 (MMP-7) and/or its precursors and fragments with MMP-7 immunoreactivity, or of circulating anti-MMP-7 antibodies, as humoral biomarkers in diagnostic in vitro methods for the detection, early detection, monitoring and/or prognosis of renal cell carcinoma (RCC) in human patients.
REFERENCES:
patent: 2004/0029200 (2004-02-01), Weimbs
patent: 2004/0253637 (2004-12-01), Buechler et al.
patent: 08-217800 (1996-08-01), None
patent: 08217800 (1996-08-01), None
patent: 10287700 (1998-10-01), None
patent: 02082076 (2002-10-01), None
Sumi et al (Oncology Reports, 2003, 10: 567-570).
Ohuchi et al (Clinica Chimica Acta, 1996, 244: 181-198).
Sherief et al (The Journal of Urology, Apr. 2003, 169: 1530-1534).
Yasunori et al (JP 08217800; Aug. 27, 1996).
Boer, J.M., Huber W.K., Sultmann H. Identification and classification of differentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500-element cDNA array. Genome Research 2001 11: 1861-1870.
European Office Action for EP Application No. 06 791 599.1-1223 issued on Oct. 3, 2009.
International Search Report for PCT/EP2006/008212 filed Aug. 21, 2006.
Kallakury et al., “Increased expression of matrilysin (MMP7) and stromelysin (MMP3, MMP10, MMP11) proteins as predictors of survival in RCCs.” Modern Pathology, vol. 16(1), Jan. 2003, p. 155A, Abstract 707.
Lein et al., “Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma”, International Journal of Cancer, Mar. 15, 2000, vol. 85(6), 801-804.
Sumi et al., “Expression of matrix metalloproteinases 7 and 2 in human renal cell carcinoma”, Oncology Reports, May-Jun. 2003, vol. 10(3), 567-570.
Struckmann et al., “MMP and TIMP expression are relevant for renal cancer progression”, Pathology Research and Practice, vol. 199(4), 2003, Abstract 297.
Wilson et al., “Matrilysin: An Epithelial Matrix Metalloproteinase with Potentially Novel Functions”, Int. J. Biochem. Cell Biol., vol. 28(2) 123-136, 1996.
Van Wart et al., “The cysteine switch: A principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family”, Proc. Natl. Acad. Sc. USA, vol. 87, Jul. 1990, 5578-5582.
Imai et al., “Matrix Metalloproteinase 7 (Matrilysin) from Human Rectal Carcinoma Cells”, The Journal of Biological Chemistry, vol. 270(12), Mar. 24, 1995, 6691-6697.
Sherief et al., “Matrix Metalloproteinase Activity in Urine of Patients with Renal Cell Carcinoma Leads to Degradation of Extracellular Matrix Proteins: Possible Use as a Screening Assay”, The Journal of Urology, vol. 169, Apr. 2003, 1530-1534.
Shimazui et al., “Complex Cadherin Expression in Renal Cell Carcinoma”, Cancer Research 56, Jul. 15, 1996, 3234-3237.
Vogelzang et al., “Kidney cancer”, The Lancet 1998, vol. 352, Nov. 21, 1998, 1691-96.
Nagase et al., “Matrix Metalloproteinases”, The Journal of Biological Chemistry, vol. 274(31), Jul. 30, 1999, 21491-21494.
Yamamoto et al., “Expression of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Human Pancreatic Adenocarcinomas: Clinicopathologic and Prognostic Significance of Matrilysis Expression”, Journal of Clinical Oncology, vol. 19(4), Feb. 15, 2001, 1118-1127.
Reynolds et al., “The functional balance of metalloproteinases and inhibitors in tissue degradation: relevance to oral pathologies”, J.R. Coll. Surg. Edinb., vol. 42, Jun. 1997, 154-160.
Ohuchi et al., “A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 7 (matrilysin) using monoclonal antibodies”, Clinica Chimica Acta 244 (1996) 181-198.
Flickinger et al., “Post-obstruction rat sperm autoantigens identified by two-dimensional gel electrophoresis and western blotting”, Journal of Reproductive Immunology 43 (1999) 35-53.
Korneeva et al., “Serum antibodies to the 27-kd heat shock protein in women with gynecologic cancers”, American Journal of Obstetrics and Gynecology, vol. 183(1), 18-21, 2000.
Mathis, Gerard, “Rate Earth Cryptates and Homogeneous Fluoroimmunoassays with Human Sera”, Clinical Chemistry, vol. 39(9), 1993, 1953-1958.
Birkedal-Hansen et al., “Matrix Metalloproteinases: A Review”, Critical Reviews in Oral Biology and Medicine, 4(2): 1993, 197-250.
Shiomi et al., “MT1-MMP and MMP-7 in invasion and metastasis of human cancers”, Cancer and Metastasis Reviews 22, 2003, 145-152.
Rak et al., “Consequences of angiogenesis for tumor progression, metastasis and cancer therapy”, Anti-Cancer Drugs 1995, vol. 6, 3-18.
Senota et al., “Relation of matrilysis messenger RNA expression with invasive activity in human gastric cancer”, Clinical & Experimental Metastasis, vol. 16(4), 1998, 313-321.
McDonnell et al., “Expression and Localization of the Matrix Metalloproteinase Pump-1 (MMP-7) in Human Gastric and Colon Carcinomas”, Molecular Carcinogenesis 4, 1991, 527-533.
Tanimoto et al., “The Matrix Metalloprotease Pump-1 (MMP-7, Matrilysin): A Candidate Marker/Target for Ovarian Cancer Detection and Treatment”, Tumor Biology 1999, 20, 88-98.
Hofmann et al., “Prognostic Value of Urokinase Plasminogen Activator and Plasminogen Activator Inhibitor-1 in Renal Cell Cancer”, The Journal of Urology, vol. 155, Mar. 1996, 858-862.
Kugler et al., “Expression of Metalloproteinase 2 and 9 and their Inhibitors in Renal Cell Carcinoma”, The Journal of Urology, vol. 160, Nov. 1998, 1914-1918.
Sires et al., “Matrilysin is Much More Efficient than Other Matrix Metalloproteinases in the Proteolytic Inactivation of alpha-1 Antitrypsin”, Biochemical and Biophysical Research Communications, vol. 204(2), Oct. 28, 1994, 613-620.
Murphy et al., “Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan”, Biochem Journal 1991, vol. 277, 277-279.
Adachi et al., “Clinicopathologic and Prognostic Significance of Matrilysin Expression at the Invasive Front in Human Colorectal Cancers”, Int. J. Cancer, vol. 95, 2001, 290-294.
Yoshimoto et al., “Expression of MMP-7(PUMP-1) mRNA in Human Colorectal Cancers”, Int. J. Cancer, vol. 54, 1993, 614-618.
Kotera et al., “Humoral Immunity against a Tandem Repeat Epitope of Human Mucin MUC-1 in Sera from Breast, Pancreatic, and Colon Cancer Patients”, Cancer Research 54, Jun. 1, 1994, 2856-2860.
Unwin et al., “Urological malignancies and the proteomic-genomic interface”, Electrophoresis 1999, vol. 20, 3629-3637.
Blay et al., “Serum Level of Interleuken 6 as a Prognosis Factor in Metastatic Renal Cell Carcinoma”, Cancer Research, vol. 52, Jun. 15, 1992, 3317-3322.
Kleiner et al., “Matrix metalloproteinases and metastasis”, Cancer Chemotherapy Pharmacol, 1999, 43, S42-S51.
Darbouret Bruno
Sarkissian Gaiané
Aeder Sean E
Cezanne S.A.S.
Heslin Rothenberg Farley & & Mesiti P.C.
LandOfFree
In vitro method for diagnosing and monitoring renal cell... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with In vitro method for diagnosing and monitoring renal cell..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and In vitro method for diagnosing and monitoring renal cell... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2722236